Devenir un investisseur
Technologie propriétaire - Nos capacités d'analyse avancées offrent à Genembryomics un avantage concurrentiel dans la précision, la vitesse et le coût de la détection.
Premier avantage de moteur - Nous sommes la première entreprise offrant un dépistage génomique d'embryons complet.
Faire une différence - nous aidons à créer des générations sans maladie, offrant une immense valeur aux familles et à la société.
Vous voulez en savoir plus sur la façon dont Genembryomics transforme le dépistage génétique avant la grossesse?Envoyez-nous un courriel à investig @gembryomics.com.
Contactez-nous
Planification réservée aux communiqués de presse
September 19, 2023
Unlocking the Potential of IVF with GenEmbryomics’ Advanced Genomic Solutions
The rapidly progressing landscape of medical technology continually broadens the horizon for ground-breaking healthcare solutions. GenEmbryomics, with its revolutionary approach to reproductive medicine, is pioneering this shift. Our innovative application of Preimplantation Genetic Testing using Whole Genome Sequencing (PGT-WGS) is changing the future of IVF, offering unprecedented advantages to those embarking on their parenthood journey. Demystifying PGT-WGS Whole genome sequencing is a comprehensive method that determines the complete DNA sequence of an organism's genome at a single time. PGT-WGS enhances the traditional approach to gene testing. We examine the entire genome of an embryo before it is implanted, allowing us to identify potential genetic abnormalities that could lead to disease, giving us a more comprehensive understanding of the embryo's genetic health. The Advantages of PGT-WGS The journey to parenthood can be filled with uncertainty. PGT-WGS offers a unique advantage by providing prospective parents with an in-depth understanding of the genetic health of their future child. With this information, physicians can make better-informed decisions, increasing the chances of a successful pregnancy and reducing the risk of genetic diseases. GenEmbryomics: Shaping the Future of Reproductive Medicine With our commitment to pushing the boundaries of genomic technology, GenEmbryomics is a driving force in the evolution of reproductive medicine. By offering PGT-WGS, we provide a promising solution for those seeking a successful IVF outcome. We are revolutionizing reproductive medicine by offering couples more control over their reproductive choices. In Conclusion The world of reproductive medicine is evolving, and GenEmbryomics is at the forefront of this change. Through the power of PGT-WGS, we are helping families begin their journey to parenthood with more confidence and less uncertainty.
September 19, 2023
The Power of PGT-WGS: Revolutionizing the Future of Fertility Treatment
In today's rapidly evolving medical landscape, the possibilities for innovation are limitless. At GenEmbryomics, we are at the cutting edge of this transformation, driving breakthroughs in fertility treatment through our groundbreaking Preimplantation Genetic Testing using Whole Genome Sequencing (PGT-WGS). Understanding PGT-WGS PGT-WGS goes beyond traditional gene testing approaches. It involves the comprehensive scanning of an embryo's genome before implantation. By doing so, we can identify potential genetic variants that might lead to diseases. Unlike standard gene panels, PGT-WGS provides a comprehensive picture of the genetic health of an embryo. Why Choose PGT-WGS? Fertility treatment is a journey, often fraught with uncertainty. PGT-WGS provides potential parents with a unique level of insight into their future child's genetic health. By using PGT-WGS, physicians can make better-informed decisions, increasing the potential for successful implantation and reducing the risk of genetic diseases. GenEmbryomics: At the Forefront of Innovation At GenEmbryomics, we understand the immense potential of genomic technology in transforming the field of reproductive medicine. Our PGT-WGS technology offers a promising solution to couples seeking successful IVF outcomes. It allows for a more comprehensive understanding of an embryo’s genetic health, providing reassurance and hope to prospective parents. In Conclusion The world of fertility treatment is evolving, and GenEmbryomics is proud to be leading the charge with PGT-WGS. We are committed to harnessing the power of technology to improve lives, offering families the chance to embark on their journey towards parenthood with confidence.
September 19, 2023
Study Shows Benefits of Comprehensive Genomic Screening for IVF Embryos
A new study highlights the power of rapid whole genome sequencing (rWGS) for providing genetic insights that can critically impact medical care. The findings have important implications for preimplantation genetic testing using WGS (PGT-WGS) during IVF. In the study, published in JAMA Network Open, researchers performed rWGS on over 200 critically ill newborns suspected of having genetic diseases. rWGS provided a genetic diagnosis for 57% of infants compared to just 34% using standard targeted gene panels. Nearly twice as many diagnoses shows the superior detection ability of comprehensive genomic sequencing versus selective gene screening. Based on the genetic findings, physicians could make better informed treatment decisions in 70% of cases where a diagnosis was achieved. This demonstrates the value of broad genomic screening to uncover disease-associated variants across the genome. Standard selective screens simply cannot match this level of clinical insight. Currently, most IVF clinics rely on targeted PGT testing panels analyzing a limited set of genes. But as this study shows, selective screening can easily miss genetic abnormalities linked to serious diseases. By adopting PGT-WGS, IVF clinics can comprehensively screen embryos for thousands of disease-causing variants. This minimizes the chances of implanting an embryo with an undetected genetic defect. Just as with the infants, detecting embryo abnormalities early is critical to inform care. By enabling deeper genetic analysis, PGT-WGS provides unmatched embryo risk profiling for IVF patients. This study adds to the mounting evidence for comprehensive genomic screening in medical care and reproductive medicine. The clinical benefits of PGTWGS can be life changing, and technology promises to become a vital tool for evaluating embryo viability. One of the unique advantages of GenEmbryomics' PGT-WGS technology is that it allows detection of genetic abnormalities in embryos prior to pregnancy. This gives families invaluable insights into genetic health and the ability to select the healthiest embryo before transfer. Unlike prenatal testing during pregnancy or whole genomic screening after birth, GenEmbryomics empowers parents with information to reduce genetic disease risk before conception occurs. Performing the comprehensive screening at this early pre-pregnancy stage with IVF gives families reproductive autonomy and avoids facing difficult decisions later in pregnancy. By shifting the timeline earlier, GenEmbryomics delivers profound benefits prior to pregnancy with PGT-WGS.